Partner Content Partner Content 1 week to SMi’s Superbugs & Superdrugs - REMOTE ACCESS ONLY 1 week to Superbugs & Superdrugs - REMOTE ACCESS ONLY
Partner Content Partner Content Interview with Martin Everett speaker at SMi’s Superbugs & S... Interview with Martin Everett speaker at Superbugs
Partner Content Partner Content Exclusive Interview with Martin Everett, CSO, Antabio, speak... Exclusive Interview with Martin Everett
Partner Content Partner Content Combioxin Speaking at SMi's 22nd Annual Superbugs & Superdru... Combioxin Speaking at SMi's 22nd Annual Superbugs
Partner Content Partner Content SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020 – S... SMi’s 22nd Annual Superbugs & Superdrugs Conference
Partner Content Partner Content Genentech develop Antibiotic with potential to lead to new c... Superbugs & Superdrugs 2019
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
